Abstract
The aim of this study was to compare the action of three multidrug resistance (MDR) modulators, cyclosporine A, S 9788, and verapamil, on the efflux of two anthracyclines, doxorubicin and daunorubicin, and of daunorubicinol, the C-13 alcohol metabolite of daunorubicin. Rat-hepatocyte primary cultures have been used as a model of P-glycoprotein (Pgp) expression. This model allows the study of MDR at different levels of Pgp expression, which increases in parallel with the time in culture; furthermore, the hepatocytes are capable of metabolizing drugs, which enables the determination of the role of Pgp on metabolite efflux. All modulators tested were incubated for 6 h at concentrations of 1, 5, and 15 μM with doxorubicin (0.5 μM) and at 1 and 15 μM with daunorubicin (0.5 μM) on hepatocytes grown for 4 and 48 h in culture. Daunorubicinol (0.5 μM) was tested with modulators at 48 h of culture. In fresh hepatocytes, the three MDR modulators did not induce an increase in the intracellular retention of anthracycline as compared with controls (no MDR modulator). At 48 h of culture, the three test drugs increased doxorubicin intracellular accumulation. In contrast, daunorubicin rubicin retention was not modified, but that of its metabolites was increased. Within the concentration range tested, cyclosporine was the most potent modulator without dose-dependent activity. The activity rank order was cyclosporine > S 9788 > verapamil. Cyclosporine and S 9788 were as active in coincubation as in preincubation with anthracyclines. Verapamil had no action when incubated before the addition of anthracyclines. Cyclosporine and S 9788 had an effect on the intracellular retention of daunorubicinol used alone whereas verapamil did not. The action of cyclosporine and S 9788 on the retention of daunorubicinol proves that at least a part of the efflux of C-13 alcohol metabolites of anthracyclines is mediated by Pgp. This study shows that S 9788, cyclosporine, and verapamil are MDR modulators in hepatocytes with high-level Pgp expression. This study also demonstrates that hepatocytes are a potent tool for the study of the action of new MDR modulators on cytostatic drugs as well as on their metabolites.
Similar content being viewed by others
References
Baurain R, Deprez-De Campaneere D, Trouet A (1979) Determination of daunorubicin, doxorubicin and their fluorescent metabolites by high pressure chromatography: plasma levels in DBA2 mice. Cancer Chemother Pharmacol 2: 11
Benchekroun MN, Pourquier P, Schott B, Robert J (1993) Doxorubicin-induced lipid peroxidation and glutathione-peroxidase activity in tumor-cell lines selected for resistance to doxorubicin. Eur J Biochem 211: 141–146
Berman E, McBride M (1992) Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 12: 3267
Bradley G, Juranka PF, Ling V (1988) Mechanism of multidrug resistance. Biochim Biophys Acta 948: 87
Dhainaut A, Régnier G, Atassi G, Pierré A, Léonce S, Kraus-Berthier L, Prost JF (1992) New triazidine derivatives as potent modulators of multidrug resistance. J Med Chem 35: 2483
Fardel O, Ratanasavanh D, Loyer P, Ketterer B, Guillouzo A (1992) Overexpression of the multidrug resistance gene product in adult rat hepatocytes during primary culture. Eur J Biochem 205: 847
Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155
Friche E, Jensen PB, Nissen NI (1992) Comparison of cyclosporin A and SDZPSC 833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor. Cancer Chemother Pharmacol 30: 235
Guguen C, Guillouzo A, Boisnard M, Le Cam A, Bourel M (1975) Etude ultrastructurale de monocouches d'hépatocytes de rats adultes cultivés en présence d'hémisuccinate d'hydrocortisone. Biol Gastroenterol 8: 223
Huet S, Chapey C, Robert J (1993) Reversal of multidrug resistance by a new lipophilic cationic molecule S 9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells. Eur J Cancer 29A: 137
Israel M, Pegg WJ, Wilkinson PM, Garnick MB (1978) Liquid chromatography analysis of adriamycin and metabolites in biological fluids. J Liquid Chromatogr 1: 795
Kuffel MJ, Reid JM, Ames MM (1992) Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in cultures. Cancer Chemother Pharmacol 30: 51
Le Bot MA, Bégué JM, Kernaleguen D, Robert J, Ratanasavanh D, Airiau J, Riché C, Guillouzo A (1988) Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes. Biochem Pharmacol 37: 3877
Le Bot MA, Swirsky-Simon H, Kernaleguen D, Riché C (1994) P-glycoprotein expression and function in rat hepatocytes in culture. Biochem Pharmacol 47: 2302
Naito M, Tsuruo T (1989) Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug resistant K562 cells without calcium ion involvement. Cancer Res 49: 1452
Nooter K, Sonneveld P, Jansenn A, et al (1990) Overexpression of the MDR-1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin A. Int J Cancer 45: 263
Osann K, Sweet P, Slater LM (1992) Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemic cells in vitro. Cancer Chemother Pharmacol 30: 152
Pastan I, Gottesman M (1987) Multiple-drug resistance in human cancer. New Engl J Med 316: 1388
Pérez V, Pierré A, Léonce S, Anstett M, Prost JF, Atassi G (1993) Caractérisation in vitro de l'activité du S 9788, un nouveau modulateur de la résistance multidrogue. Bull Cancer 80: 310
Pierré A, Dunn TA, Kraus-Berthier L, Léonce S, Saint-Dizier D, Régnier G, Dhainaut A, Berlion M, Bizzari JP, Atassi G (1992) In vitro and in vivo circum vention of multidrug resistance by Servier 9788, a novel triazino amino piperidine derivative. Invest New Drugs 10: 137
Robert J, Gianni L (1994) Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 17 (in press)
Schott B, Robert J (1989) Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Biochem Pharmacol 38: 4069
Sonneveld P, Nooter K (1990) Reversal of drug resistance by cyclosporin A in a patient with acute myelocytic leukaemia. Br J Haematol 75: 208
Spoelstra EC, Westerhoff HV, Dekker H, Lankelma J (1992) Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells. Eur J Biochem 207: 567
Vasanthakumar G, Ahmed N (1985) Uptake and metabolism of daunorubicin by human myelocytic cells. Cancer Chemother Pharmacol 15: 35
Woodcock DM, Jefferson S, Linsenmeyer ME, Crowther JP, Chojnowski GM, Williams B, Bertoncello I (1990) Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 50: 4199
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Le Bot, MA., Kernaleguen, D., Robert, J. et al. Modulation of anthracycline accumulation and metabolism in rat hepatocytes in culture by three revertants of multidrug resistance. Cancer Chemother. Pharmacol. 35, 53–58 (1994). https://doi.org/10.1007/BF00686284
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686284